Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Locatelli, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Locatelli, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2004) 19: v15-v19
Nephrol Dial Transplant Vol. 19 Suppl 5 © ERA–EDTA 2004; all rights reserved

The need for better control of secondary hyperparathyroidism

Francesco Locatelli

Department of Nephrology and Dialysis, Ospedale A. Manzoni, Lecco, Italy

Correspondence and offprint requests to: Professor Francesco Locatelli, Department of Nephrology and Dialysis, Ospedale A. Manzoni, 23900 Lecco, Italy. Email: nefrologia{at}ospedale.lecco.it

Abstract

Secondary hyperparathyroidism (SHPT), a frequent complication of chronic kidney disease, develops in response to an imbalance in the serum levels of calcium, phosphorus and vitamin D as a result of altered metabolism. Raised serum levels of parathyroid hormone (PTH) and calcium–phosphorus product have a major effect on morbidity and mortality in dialysis patients. The new Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines, formulated by the National Kidney Foundation in the USA, propose strict targets for the control of serum levels of PTH, calcium and phosphorus. Meeting these targets will be a challenge for clinicians, because the traditional therapies for SHPT, such as vitamin D sterols and calcium-based phosphate binders, often exacerbate mineral imbalances. Results from a number of recent studies indicate that the majority of haemodialysis patients currently do not meet these new targets. Thus, there is a definite need to improve PTH, calcium and phosphate management of dialysis patients to reduce the incidence of uraemic bone disease and related disturbances of mineral metabolism as well as their unacceptably high cardiovascular morbidity and mortality.

Keywords: clinical trial; parathyroid hormone; secondary hyperparathyroidism; serum calcium; serum phosphorus


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
F. Locatelli, N. Dimkovic, G. Pontoriero, G. Spasovski, S. Pljesa, S. Kostic, A. Manning, H. Sano, and S. Nakajima
Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study
Nephrol. Dial. Transplant., September 7, 2009; (2009) gfp445v1.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.